Market Access MAPs, EAPs, and patient access: Suzanne Aitken on the challe... Suzanne Aitken, SVP of managed access at Clinigen, discussing the role of managed access programmes in the current pharmaceutical landscape.
Digital The TechBio way: Brendan Frey talks genomics, AI, and RNA pharmaphorum speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation.
Oncology Advancing the frontiers of cancer diagnostics: Post-ASCO wit... Post-ASCO 2025, Eric Matthews, chief business officer at Caris Life Sciences, discusses advancing the frontier of cancer diagnostics and treatment.
Sales & Marketing Compliance baked into the design core: On AI in life science... In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Florian Schnappauf, VP, enterprise commercial strategy Europe, at Veeva Systems.
News MSD stops trials of BTK inhibitor for blood cancers MSD has stopped development of BTK inhibitor nemtabrutinib, acquired via its $2.7bn takeover of ArQule, after trial results pointed to a safety issue.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.